Actively Recruiting
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Led by Ain Shams University · Updated on 2024-07-11
64
Participants Needed
2
Research Sites
46 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this controlled, randomized, clinical trial is to evaluate the effect of vinpocetine on clinical outcomes on the diabetic nephropathy patients. The following will be evaluated; anthropometrics, kidney functions, glucose panel, lipid panel, ICAM-1, quality of life. Participants will receive either vinpocetine or placebo, twice daily for 3 months.
CONDITIONS
Official Title
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of type 2 diabetes with chronic kidney disease stage 3 (eGFR 30-59 ml/min) or stage 4 (eGFR 15-29 ml/min)
- Albumin/Creatinine ratio between 30 and 300 micrograms per milligram
- Stable standard therapy for diabetes and hypertension for at least three months before joining the study
You will not qualify if you...
- Kidney donor or recipient
- Active cancer
- Pregnant or breastfeeding
- Known allergy or intolerance to vinpocetine
- Currently participating in other interventional clinical trials
- Liver function tests (ALT and AST) more than three times the upper normal limit
- Severe other medical conditions
- Taking warfarin medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Ain Shams University Hospital
Cairo, Abbasseia, Egypt, 11588
Not Yet Recruiting
2
Ain Shams Hospitals
Cairo, Abbasseya, Egypt, 11588
Actively Recruiting
Research Team
T
Tamer El Said
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here